A European perspective on oncology: ASCO review

An overview of the latest on immunotherapies, progress in multiple myeloma and benefits of patient-reported outcomes.

Digital healthcare round-up: ASCO apps, public health, weara...

A round-up of this week's top digital healthcare news. Marco Ricci reports.

Potential lung cancer use for Novartis' melanoma combo

New trial suggests use in lung cancer with same mutation.

Ibrance approval cemented as competition comes into view

In February 2015,  Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-men

Eye on ASCO Day 4 - Moonshots, Money and Mobile apps

You don't often get searched by the US secret service at a medical meeting.

Does NEMO bring us a step closer in the fight against melano...